Compare VVR & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VVR | KMDA |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.9M | 460.3M |
| IPO Year | 1998 | 2013 |
| Metric | VVR | KMDA |
|---|---|---|
| Price | $2.94 | $7.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 659.4K | 183.3K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.94 |
| Revenue Next Year | N/A | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.91 | $6.50 |
| 52 Week High | $3.54 | $9.35 |
| Indicator | VVR | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 50.37 |
| Support Level | $2.95 | $6.89 |
| Resistance Level | $2.96 | $8.05 |
| Average True Range (ATR) | 0.02 | 0.21 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 90.00 | 2.99 |
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective is to provide a high level of current income, consistent with preservation of capital. The Trust seeks to achieve its objectives by investing in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions. The Trust borrows money for investment purposes, which may create the opportunity for enhanced return, but also should be considered a speculative technique and may increase the Trust's volatility.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.